The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this initiative within a general cardiology practice.

RemeGen has submitted a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for IgAN, which if approved would ...

Iptacopan, an oral factor B inhibitor, previously received accelerated approval in 2024 under the brand name Fabhalta for IgAN, specifically to reduce proteinuria in patients at risk of rapid disease ...

KDIGO's new IgA nephropathy guideline shifts the treatment paradigm from supportive care alone to targeting the disease's immunologic nature.

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR ...

Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tabletsU.S. losartan ...